Adcendo

Adcendo was founded in 2017, is headquartered in Copenhagen, Denmark, lists 11–50 employees, and has $265.0M in recorded funding across 3 rounds.

Headquarters
Copenhagen
Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$265.0M
Last Round
$75.0M Series CApr 2026
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 7 investors for this company. The full record is or through the API.

About

Adcendo is a clinical-stage Copenhagen biotech developing antibody-drug conjugates (ADCs) for underserved cancers, spun out in 2017 from the Finsen Laboratory of Rigshospitalet and the University of Copenhagen by Niels Behrendt, Lars Henning Engelholm, Christoffer Nielsen, and biotech entrepreneur Henrik Stage. Lead program ADCE-D01, the first uPARAP-targeted ADC with a topoisomerase-inhibitor payload, holds FDA Fast Track designation for soft tissue sarcoma and is enrolling the ADCElerate1 dose-escalation and expansion study in mesenchymal cancers. The company, led by CEO Michael Pehl, closed an oversubscribed $75 million Series C in April 2026 led by Jeito Capital with new investors Vida Ventures, Bpifrance, and Denmark’s EIFO, funding three clinical ADC programs through upcoming milestones.

Summary

Adcendo is a Biotech company based in Copenhagen, Denmark, founded in 2017. It lists 11–50 employees. It has raised $265.0M in total across 3 rounds, most recently a $75.0M Series C round in Apr 2026. Investors include Jeito Capital, Novo Holdings A/S and RA Capital Management.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CApr 2026
$75.0M

Sign up to see all 3 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Adcendo on Indexed.vc
<a href="https://indexed.vc/companies/adcendo"><img src="https://indexed.vc/api/badge/company/adcendo" alt="Adcendo on Indexed.vc" width="260" height="76" /></a>